Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CLL1-CD33-NKG2D bicephalic CAR-T cells
- Development stage
- Phase 2
- Lead developer
- Xuzhou Medical University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-CLL1-CD33-NKG2D bicephalic CAR-T cells is an investigational autologous chimeric antigen receptor (CAR) T-cell therapy being developed by Xuzhou Medical University for the treatment of relapsed or refractory acute myeloid leukemia (AML). This multi-targeted therapy is designed to simultaneously recognize three distinct antigens expressed on AML cells: C-type lectin-like molecule-1 (CLL1), CD33, and ligands for the NKG2D receptor. By targeting multiple markers, the therapy aims to enhance the elimination of leukemia cells and reduce the risk of immune escape caused by antigen loss, a common challenge in single-target CAR-T therapies. The treatment involves collecting a patient's T cells via apheresis, genetically engineering them to express the specific CARs, and reinfusing them into the patient following lymphodepletion. It is currently being evaluated in Phase I/II clinical trials.
- Other names
- anti-CLL1-CD33-NKG2D Bicephali CAR-T cellsanti-CLL-1-CD33-NKG2D Bicephali CAR-T cellsanti-CLL 1-CD33-NKG2D Bicephali CAR-T cells
02
Targets
CD33 (Myeloid cell surface antigen CD33)CLEC12AMICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on anti-CLL1-CD33-NKG2D bicephalic CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CLL1-CD33-NKG2D bicephalic CAR-T cells.